Jubilant realigns leadership roles in US subsidiaries

Jubilant Organosys Ltd. has realigned the leadership roles in its two newly acquired entities, HollisterStier Laboratories LLC and DRAXIS Specialty Pharmaceuticals Inc. (“DRAXIS”), operating in USA and Canada respectively, to leverage on their complimentary strengths.

The move will result in cohesive operations, focus on research and development and product innovation in the areas of specialty pharmaceuticals, and will consolidate Jubilant’s leadership in the areas of both sterile and non-sterile contract manufacturing by leveraging multi-site capabilities, a Jubilant statement said.

 Jean Pierre Robert, chief executive officer for the specialty pharmaceutical organization will thus be responsible for the radiopharmaceuticals business of DRAXIS as well as the allergy extracts business of Hollister-Stier Laboratories.

Similarly, Marcelo Morales,  appointed as the CEO for Contract Manufacturing, and will have responsibility of the sterile injectables manufacturing arm of HollisterStier and the sterile injectable, semisolids and solid dose manufacturing operations of DRAXIS.

“ This strategic realignment will enable us to drive value for our customers through synergistic operations and will offer exciting opportunities for all of us ,” said Jubilant Organosys Chairman and Co-Chairman, Shyam and Hari Bhartia.

“ With a focus on continuous innovation, expansion of service offerings and locations we ensure that our customers receive the desired level of quality, flexibility and expertise to meet the market demands.” they added.